Low dose isotretinoin for pigmented post-varicella scars

Dave, Dharmendra Dineshchandra; Abdelmaksoud, Ayman

doi:10.1111/dth.12768

Cited by 4 publications

(6 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Al-Hamamy, Salman, & Abdulsattar, 2012;Miljkovic, 2012;Rallis et al, 2008), (b) Treatment of different clinical variants, (c) Marked improvement after 1 month of commencing therapy, (d) Significant improvement of post-healing pigmentation and scarring of the previous irritating treatment, that may confirm our hypothesis, and experience with post-varicella scarring(Dave & Abdelmaksoud, 2018), and (e) The duration of remission was extended for up to 3 years (till writing this report) in one case(Figures 1-5).…”

supporting

confidence: 64%

Low dose isotretinoin as an adjuvant therapy for treatment of different clinical variants of warts: A case series

Dave¹,

Abdelmaksoud

2019

Dermatologic Therapy

Self Cite

View full text Add to dashboard Cite

Warts constitute the most frequently observed dermatological manifestations of human papillomavirus (HPV). Although an extensive range of treatments exist for local warts, there is no specific therapy based on high‐quality evidence of notable treatment success or high cure rate, or minimal adverse effects. Recalcitrant warts are, therefore, a common therapeutic problem. This case series refer to 14 immunocompetent patients with recalcitrant warts, who experienced full resolution of their warty lesions when treated with addition of low dose isotretinoin, in a dose of 0.1–0.2 mg/kg/day, for a 3‐month course, with no significant adverse effects. Long‐term remission was noted for up to 3 years with no signs of active lesions. Low dose isotretinoin should be in the priority of the treatment options of recalcitrant warts, alone or in combination.

show abstract

supporting

confidence: 64%

Low dose isotretinoin as an adjuvant therapy for treatment of different clinical variants of warts: A case series

Dave¹,

Abdelmaksoud

2019

Dermatologic Therapy

Self Cite

View full text Add to dashboard Cite

show abstract

“…Although aggressive therapy or choosing therapeutic lines of high‐grade acne in lower ones is currently accepted and even suggested by the experts of isotretinoin, worries about its side effects, misconception, and lack of proper awareness may make patients refuse using it and even their parents may have a prejudice about prescribing it to their children 30,31 . Results of the current study suggest that if dermatologists could detect patients who will most probably form postacne scars, they would be more able to convince them to use this aggressive therapy as a protective measure or even as an early treatment line as suggested for pigmented post‐varicella scars 32 . However, clinically, it is difficult to predict which acne vulgaris case will develop postacne scarring.…”

Section: Discussionmentioning

confidence: 89%

MMP‐1 (519 A/G) and TIMP‐1 (372 T/C) genes polymorphism in an Egyptian sample of Acne vulgaris patients

Mohammed¹,

Sabry

Ameen

et al. 2021

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Background Different Matrix metalloproteinases (MMPs) family members may be implicated in acne vulgaris development. However, there are no published data about the role of MMP‐1 and TIMP‐1 gene polymorphisms in acne vulgaris development. Aims To evaluate the association between MMP‐1 (519 A/G) and TIMP‐1 (372 T/C) gene polymorphisms and the risk of developing acne vulgaris among a sample of Egyptian acne patients. Patients/Methods This case‐control study included 100 acne vulgaris patients and 120 apparently healthy control subjects. Acne severity was assessed according to Global Acne Grading System (GAGS). MMP‐1 (519 A/G) and TIMP‐1 (372 T/C) gene polymorphisms were investigated using RFLP‐PCR technique. Results The MMP‐1 (519 A/G) AG and GG genotypes and G allele increase the risk of acne vulgaris~2–3 folds. In female patients, TIMP‐1 (372 C/T) TT genotype and T allele showed significantly higher frequency in cases compared with the control group (p = 0.004, 0.001 respectively) with a higher risk to develop acne. On the other hand, in male patients, there was insignificant difference between the frequency of alleles in patients and control subjects. TIMP‐1 (372C/T) TT genotype has been shown to be significantly detected in the studied female patients associated with the positive family history of the disease, and it increases the risk of back affection, severe acne grade development, and the liability to postacne scar formation. Conclusion MMP‐1 (519 A/G) and TIMP‐1 (372 T/C) gene polymorphisms may be related to acne vulgaris development.

show abstract

“…Drugs had to be taken every other night for a duration of 1 to 4 months. In the follow-up visits, all the patients had moderate to excellent responses ( 13 ).…”

Section: Resultsmentioning

confidence: 99%

“…Combination therapies including intradermal incision with Er:YAG and also, Microdermabrasion with Nd:YAG laser, were also effective, resulting in marked improvements ( 37 , 38 ). In systemic medical treatments, the off-label use of topiramate and isotretinoin revealed marked improvements, but they are used limitedly in practice ( 13 , 14 ).…”

Section: Discussionmentioning

confidence: 99%

Varicella-Zoster Scar Treatments: A Tertiary Review

Mohammad

Ghassemi

2021

Med. J. Islam. Republ. Iran

View full text Add to dashboard Cite

show abstract

Low dose isotretinoin for pigmented post-varicella scars

Abstract: A 14-year-old girl, Fitzpatrick III photo skin type, presented with a 5-month history of disfiguring pigmented chickenpox scarring. She had deep, atrophic, monomorphic, boxcar like scars with associated hyperpigmentation. In addition she had polymorphic papulopustular

Cited by 4 publications

References 6 publications

Low dose isotretinoin as an adjuvant therapy for treatment of different clinical variants of warts: A case series

Low dose isotretinoin as an adjuvant therapy for treatment of different clinical variants of warts: A case series

MMP‐1 (519 A/G) and TIMP‐1 (372 T/C) genes polymorphism in an Egyptian sample of Acne vulgaris patients

Varicella-Zoster Scar Treatments: A Tertiary Review

Contact Info

Product

Resources

About